Antifungal therapeutic drug monitoring: established and emerging indications. - Wikidata - awgldk - TriplyDB

Antifungal therapeutic drug monitoring: established and emerging indications.

Antifungal therapeutic drug monitoring: established and emerging indications.

http://www.wikidata.org/entity/Q37310029

about

Recent advances in the management of mucormycosis: from bench to bedside Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients How to manage aspergillosis in non-neutropenic intensive care unit patients Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations Cryptococcal meningitis: epidemiology and therapeutic options.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer.Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children.Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents.Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Therapeutic drug monitoring of antimicrobials.Antifungal pharmacokinetics and pharmacodynamics Future directions in mucormycosis research.Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period How I treat mucormycosis.Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature In vitro study of the variable effects of proton pump inhibitors on voriconazole Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

P2860

Q24642450-F35D4062-9495-4A9C-A6A9-472D6FEDEDD4 Q26744049-898DC6F9-C245-442C-979F-9EC3C8F04A31 Q26795605-AE42BBDE-1C6A-4CE6-B2CA-B80137F95C4B Q26999448-58833614-733C-4B86-8DB2-EBF242578B6A Q27009221-721C3C42-1307-4699-911D-E9FFBE8AAB1B Q27025299-297DB2A9-A8D8-4093-BFBE-86454F026B47 Q28067726-B077227B-0218-4EEA-A2AF-5C9E1CE18D16 Q33633343-44263624-D1F5-43C8-9FDC-24B0BB1FE94C Q33827819-04D3CCB7-10D9-4A94-B95C-09022A78E57F Q34020402-1B59DA0F-2FF1-45C7-B335-BDE03D0E2AB2 Q34108484-3CC47CF7-A694-4CF4-9434-2B23145D1740 Q34138276-3C17FE6F-B119-4DD0-A6AD-9646D47ED7CC Q34150923-080B63B0-348F-4705-ABC9-03307F154735 Q34212799-8EEF1C73-ECA3-44CF-AFFA-9685B45A7DAF Q34299092-30E213AB-FB63-4A32-A2A5-9F32A62631B0 Q34309527-5D095164-79CA-4274-9B3E-FD8D9AD8D9DC Q34309603-0702233C-39E9-4123-8A2D-12942959C5E0 Q34343529-F99F4FCD-4870-4E09-9EBE-AF5D6CEF6338 Q34413393-FCA20F05-65E4-4D85-A44D-0296FA9C7018 Q34505582-EEC85C68-6DD8-48D8-99EE-5C0F7F85DD87 Q34532546-D89AF7EC-E520-4780-9A0F-944CD5F16DC8 Q34597018-A3759A9F-E795-4F54-9702-B0CBCA8B73A1 Q34737174-4DEB6863-74EB-4512-A4A3-67D78067C028 Q34737476-65A51FDE-6003-41DF-8407-90A00B9A2B58 Q34923083-7CDF8BE6-09CF-4917-9A4B-5C6DBBB42566 Q35067073-4232D4EA-D4D6-4CA3-9B51-B21CAFE35EC0 Q35086478-80908C9B-BA0B-49E9-8137-1BBB712F8F3D Q35231368-795F7E3C-9BB2-4F62-9530-71CB5E7E2561 Q35262607-33CC0FD0-3DAF-4D49-BC2D-D6056D497976 Q35270270-01901FB4-4A90-42C0-85CA-289C5C97AD66 Q35640430-BF9EBD29-013F-41CC-9585-39F28708D61D Q35663841-7C0C6B07-5538-49A8-A3C2-0D77A30CC3C7 Q35672102-E90F782F-29AD-4D7D-A4B4-A38C859E5D07 Q35748240-32D5BB51-9F6C-4E55-965F-B2DC27747CF1 Q35794484-DF3A1330-87AF-4BC0-ABE1-0F18178BF166 Q35797637-D6DB5CB3-6D42-4873-87B4-2216084AC65C Q35941502-6510D865-1A8E-44A9-B243-0870F3DFC229 Q35959484-00340150-7358-4D73-B773-A3303FC84FCF Q35960842-92331E58-EF04-4F3B-A73F-72F461C17AF0 Q36018743-E815D7DC-936F-4F01-AA25-E0FF0FF51EDD

P2860

Antifungal therapeutic drug monitoring: established and emerging indications.

http://www.wikidata.org/entity/Q37310029

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antifungal therapeutic drug monitoring: established and emerging indications.

@en

Antifungal therapeutic drug monitoring: established and emerging indications.

@nl

type

label

Antifungal therapeutic drug monitoring: established and emerging indications.

@en

Antifungal therapeutic drug monitoring: established and emerging indications.

@nl

prefLabel

Antifungal therapeutic drug monitoring: established and emerging indications.

@en

Antifungal therapeutic drug monitoring: established and emerging indications.

@nl

P1433

Q37310029-381F5E3B-3C19-4D51-BECF-E4149B61803A

P1476

Q37310029-7357FF08-9D46-46A0-B289-DA433FA32306

P2093

Q37310029-9F9FE2BF-2C22-4EF6-BA84-AB3B94F675CD

Q37310029-AE678ACF-6F21-4FFC-AC27-B8F979C4ABC9

Q37310029-F84285E8-CB1F-4285-82A3-89A825BD4A52

P2860

Q37310029-001FE83A-58C8-4D3B-9366-C2986A3C8745

Q37310029-066D9024-7D04-4B6B-A41A-382D7F3D8057

Q37310029-08447536-A239-4D1A-907A-AEF33530B192

Q37310029-089D5389-0FC8-47EA-8A70-2CE71CF1B6C9

Q37310029-0F0A8953-D416-455F-AC08-63CD42D296A5

Q37310029-0F4997F7-193D-4B90-A0C5-707CF13C5884

Q37310029-13B232E3-588B-4BCF-9071-7A400321B341

Q37310029-16D2B357-ABF3-4733-AB26-EDB0A9249721

Q37310029-1956E727-42C1-45C8-AC50-144F20A1AF16

Q37310029-1A45A373-D880-462C-9965-60DE429B9DB0

P304

Q37310029-E76D7C93-0763-4E67-9479-108EC86C9DF0

P31

Q37310029-EDF06146-1C64-4049-89A1-CA96A3E27FA7

P356

Q37310029-C1EE9BB2-4EAA-4CE5-9B7A-632EA904D3C9

P407

Q37310029-D53FA103-644A-48B6-8FF2-5FC1D2747102

P433

Q37310029-6A11AD98-ACE2-45FE-8FCF-7614B7E1EE05

P478

Q37310029-826647A8-700A-41F9-B0B3-6337DD3B8D71

P577

Q37310029-A72F1C60-8CDA-469A-B428-DB35AB9B49BF

P698

Q37310029-68F186F2-978C-4577-845D-04F7C7E2409F

P932

Q37310029-734A074B-6F61-4E98-8F2F-708EB7F1C297

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Antifungal therapeutic drug monitoring: established and emerging indications.

@en

P2093

Andres Pascual

http://www.w3.org/2001/XMLSchema#string

David Andes

http://www.w3.org/2001/XMLSchema#string

Oscar Marchetti

http://www.w3.org/2001/XMLSchema#string

P2860

Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases

Voriconazole therapeutic drug monitoring.

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Aspergillosis case-fatality rate: systematic review of the literature.

Flucytosine: correlation between toxicity and pharmacokinetic parameters.

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.

Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.

Itraconazole in cyclodextrin solution.

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.

P304

24-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00705-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18955533

http://www.w3.org/2001/XMLSchema#string

P932

2612175

http://www.w3.org/2001/XMLSchema#string